Active Ingredient(s): Miglustat
FDA Approved: * July 31, 2003
Pharm Company: * ACTELION PHARMS
Category: Enzymes

Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Zavesca 100 mg Oral Capsule
NDC: 66215-201
Actelion Pharmaceuticals Us, Inc.

Popular Topics


Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nause...